Krilogy Financial LLC Makes New Investment in Bristol-Myers Squibb (NYSE:BMY)

Krilogy Financial LLC bought a new stake in Bristol-Myers Squibb (NYSE:BMY - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 10,085 shares of the biopharmaceutical company's stock, valued at approximately $570,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of BMY. Ameritas Advisory Services LLC grew its stake in Bristol-Myers Squibb by 9.4% in the 4th quarter. Ameritas Advisory Services LLC now owns 15,807 shares of the biopharmaceutical company's stock valued at $894,000 after acquiring an additional 1,357 shares during the last quarter. HB Wealth Management LLC lifted its holdings in shares of Bristol-Myers Squibb by 17.6% in the fourth quarter. HB Wealth Management LLC now owns 73,542 shares of the biopharmaceutical company's stock valued at $4,159,000 after purchasing an additional 11,023 shares in the last quarter. Trust Co. of Vermont increased its stake in shares of Bristol-Myers Squibb by 14.2% during the 4th quarter. Trust Co. of Vermont now owns 45,051 shares of the biopharmaceutical company's stock worth $2,548,000 after purchasing an additional 5,595 shares in the last quarter. Westend Capital Management LLC purchased a new position in shares of Bristol-Myers Squibb during the 4th quarter worth approximately $38,000. Finally, Premier Path Wealth Partners LLC lifted its stake in Bristol-Myers Squibb by 5.9% in the 4th quarter. Premier Path Wealth Partners LLC now owns 33,388 shares of the biopharmaceutical company's stock valued at $1,888,000 after buying an additional 1,868 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have recently weighed in on BMY. BMO Capital Markets boosted their price target on Bristol-Myers Squibb from $57.00 to $61.00 and gave the stock a "market perform" rating in a report on Tuesday, November 12th. Barclays boosted their target price on shares of Bristol-Myers Squibb from $42.00 to $43.00 and gave the company an "underweight" rating in a research note on Monday, October 7th. Morgan Stanley raised their price target on shares of Bristol-Myers Squibb from $36.00 to $39.00 and gave the stock an "underweight" rating in a research note on Tuesday, November 12th. Bank of America reissued a "neutral" rating and issued a $63.00 price objective on shares of Bristol-Myers Squibb in a research report on Tuesday, December 10th. Finally, UBS Group lifted their target price on shares of Bristol-Myers Squibb from $50.00 to $54.00 and gave the stock a "neutral" rating in a research note on Wednesday, October 9th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, four have issued a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $56.27.

Bristol-Myers Squibb Stock Down 0.0 %

Shares of NYSE:BMY traded down $0.03 during midday trading on Monday, hitting $56.35. 10,909,530 shares of the company's stock traded hands, compared to its average volume of 10,195,547. The firm's fifty day moving average price is $57.53 and its two-hundred day moving average price is $52.09. The company has a debt-to-equity ratio of 2.83, a quick ratio of 1.09 and a current ratio of 1.24. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $61.08. The company has a market cap of $114.30 billion, a PE ratio of -15.70, a P/E/G ratio of 1.95 and a beta of 0.45.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.49 by $0.31. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The company had revenue of $11.89 billion for the quarter, compared to analysts' expectations of $11.26 billion. During the same quarter in the previous year, the firm posted $2.00 earnings per share. The firm's quarterly revenue was up 8.4% on a year-over-year basis. On average, equities research analysts anticipate that Bristol-Myers Squibb will post 0.93 EPS for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd will be paid a dividend of $0.62 per share. The ex-dividend date is Friday, January 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.40%. This is a positive change from Bristol-Myers Squibb's previous quarterly dividend of $0.60. Bristol-Myers Squibb's dividend payout ratio (DPR) is currently -69.08%.

Insider Activity

In other Bristol-Myers Squibb news, EVP Samit Hirawat acquired 1,830 shares of the company's stock in a transaction on Friday, November 1st. The shares were bought at an average cost of $54.67 per share, for a total transaction of $100,046.10. Following the acquisition, the executive vice president now directly owns 62,109 shares of the company's stock, valued at $3,395,499.03. This trade represents a 3.04 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Phil M. Holzer sold 700 shares of the stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $55.62, for a total value of $38,934.00. Following the transaction, the senior vice president now owns 11,760 shares of the company's stock, valued at approximately $654,091.20. This trade represents a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.